Loading stock data…
PHVS
$31.60+0.01 (+0.03%)
After Hours$31.60+0.00 (+0.00%)· Last close Jun 9
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pharvaris N.V. in the Healthcare sector is trading at $31.60. Wall Street consensus targets $46.17 (13 analysts), implying a +46.1% move over the next 12 months. The stock is currently near its 52-week high of $33.33, remaining 21.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +46.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$31.60
Potential Downside
0%
Whystock Fair Value$31.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Mean target$46.17+46.1%
Range$32.54 – $72.88
Fundamentals
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-71.32%
Volume
Today's trading volume
460,635
Recent News
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case
Pharvaris (NasdaqGS:PHVS) has completed a substantial equity offering to support late stage development of its lead treatment for hereditary angioedema. The company is preparing regulatory submissions, including a planned new drug application, and progressing Phase 3 trials for hereditary and acquired angioedema. This funding event comes as Pharvaris positions itself for potential commercialization of its lead product. Pharvaris enters this phase with its stock at $32.94 and a 3 year return...
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid ongoing drug development milestones.
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of strong stock performance.
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
Shares of KalVista Pharmaceuticals catapulted Wednesday on a $1.9 billion takeover offer from Italy's Chiesi Group.